Abstract:Db/db mice exhibited low vagal activity and diabetic myocardial injury, accompanied by gut microbiota dysbiosis and gut barrier dysfunction, as well as increased lipopolysaccharide (LPS) concentrations and metabolic inflammation. Importantly, pyridostigmine could protect against diabetic myocardial injury by alleviating gut microbiota dysbiosis and gut barrier dysfunction and reducing metabolic inflammation, possibly by inhibiting the LPS‐induced activation of the ERK/Egr‐1 pathway. Moreover, acetylcholine ameliorated high‐glucose (HG) and LPS‐induced cardiomyocytes injury by inhibiting the ERK/Egr‐1 pathway and inflammation through α7nAChR. Autonomic imbalance and metabolic inflammation are important pathological processes in diabetic cardiomyopathy. Gut microbiota dysbiosis and increased levels of bacterial component lipopolysaccharide (LPS) are associated with diabetic myocardial injury, but the mechanism by which gut microbes affect metabolic inflammation and cardiac injury remains unclear. We determined whether pyridostigmine (PYR), which inhibits cholinesterase to improve vagal activity, could regulate the disordered gut microbiota and attenuate gut barrier dysfunction, metabolic endotoxemia, and inflammation in diabetes. Db/db mice exhibited high blood glucose levels, insulin resistance, low vagal activity, and diabetic myocardial injury. Db/db mice also exhibited gut microbiota perturbations and subsequent disruption of gut barrier function, resulting in an influx of LPS, metabolic endotoxemia, and inflammation. PYR ameliorated the dysregulated glucose and lipid metabolism, modulated the overall structure of the gut microbiota, selectively enhanced the abundance of anti‐inflammatory bacteria, and reduced the abundance of proinflammatory and potentially pathogenic bacteria in db/db mice. Importantly, PYR enhanced vagal activity, restored gut microbiota homeostasis, and alleviated gut barrier dysfunction. Therefore, the LPS‐induced extracellular signal‐regulated kinase (ERK)/early growth response‐1 (Egr‐1) pathway and consequent metabolic inflammation were inhibited, and eventually, cardiac hypertrophy, fibrosis, oxidative stress, and dysfunction were ameliorated in db/db mice. In vitro cardiomyocyte injury was induced by exposing primary neonatal rat ventricular cardiomyocytes to high glucose (HG) and LPS. In vitro analyses showed that HG + LPS induced ERK1/2 phosphorylation, Egr‐1 expression, inflammation, and cell apoptosis, which were inhibited by acetylcholine (ACh). Alpha 7 nicotinic ACh receptor but not muscarinic 2 ACh receptor plays an important role in ACh‐mediated anti‐inflammatory effects and inhibiting the ERK/Egr‐1 pathway in HG + LPS‐administered neonatal rat ventricular cardiomyocytes. PYR and ACh ameliorated diabetic myocardial injury by inhibiting the LPS‐induced ERK/Egr‐1 pathway and metabolic inflammation. The vagus–gut–heart axis has provided new insights into the complex mechanisms of diabetes and offers novel therapeutic targets.

Pyridostigmine Protects Against Diabetic Cardiomyopathy by Regulating Gut Microbiota and Branched-Chain Amino Acid Catabolism to Attenuate Mitochondria Dysfunction

Pyridostigmine Protects Against Diabetic Cardiomyopathy by Regulating Vagal Activity, Gut Microbiota, and Branched-Chain Amino Acid Catabolism in Diabetic Mice

Pyridostigmine regulates glucose metabolism and mitochondrial homeostasis to reduce myocardial vulnerability to injury in diabetic mice.

Cholinergic drugs reduce metabolic inflammation and diabetic myocardial injury by regulating the gut bacterial component lipopolysaccharide‐induced ERK/Egr‐1 pathway

Pyridostigmine Alleviates Cardiac Dysfunction Via Improving Mitochondrial Cristae Shape in a Mouse Model of Metabolic Syndrome.

Combined Treatment with Ultrasound-Targeted Microbubble Destruction Technique and NM-aFGF-loaded PEG-nanoliposomes Protects Against Diabetic Cardiomyopathy-Induced Oxidative Stress by Activating the AKT/GSK-3β1/Nrf-2 Pathway

Dihydromyricetin Prevents Diabetic Cardiomyopathy via miR-34a Suppression by Activating Autophagy

Pyridostigmine Protects Against Cardiomyopathy Associated with Adipose Tissue Browning and Improvement of Vagal Activity in High-Fat Diet Rats.

Pyridostigmine Exerts Cardiovascular Protection Effects Via Ameliorating Damaged Mitochondrial Cristae in High Fat Diet-Induced Obese Mice

Pyridostigmine Ameliorates Cardiac Remodeling Induced by Myocardial Infarction Via Inhibition of the Transforming Growth Factor-β1/TGF-β1–Activated Kinase Pathway

Protective Effect of Pyrroloquinoline Quinone on Diabetic Cardiomyopathy in C57BL/6 Mice

Berberine Ameliorates Diabetic Cardiomyopathy in Mice by Decreasing Cardiomyocyte Apoptosis and Oxidative Stress

Fatty acid β‐oxidation and mitochondrial fusion are involved in cardiac microvascular endothelial cell protection induced by glucagon receptor antagonism in diabetic mice

Gut microbiota: A new therapeutic target for diabetic cardiomyopathy

Pyrroloquinoline quinone ameliorates diabetic cardiomyopathy by inhibiting the pyroptosis signaling pathway in C57BL/6 mice and AC16 cells

Mitochondrial damage and activation of the cytosolic DNA sensor cGAS–STING pathway lead to cardiac pyroptosis and hypertrophy in diabetic cardiomyopathy mice

Myricitrin Alleviates Oxidative Stress-induced Inflammation and Apoptosis and Protects Mice against Diabetic Cardiomyopathy

PP2Cm overexpression alleviates MI/R injury mediated by a BCAA catabolism defect and oxidative stress in diabetic mice.

Dihydromyricetin Protects Against Diabetic Cardiomyopathy in Streptozotocin-Induced Diabetic Mice.

Increasing Pyruvate Dehydrogenase Flux as a Treatment for Diabetic Cardiomyopathy: A Combined 13C Hyperpolarized Magnetic Resonance and Echocardiography Study

Mesenchymal stem cells ameliorate inflammation and pyroptosis in diabetic cardiomyopathy via the miRNA-223-3p/NLRP3 pathway